Clinical isolates of Mycobacterium simiae in San Antonio, Texas. An 11-yr review.

Valero, Gustavo; Peters, Jay I.; Jorgensen, James H.; Graybill, John R.

doi:10.1164/ajrccm.152.5.7582293

Cited by 61 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Repeated water surveys, however, did not fi nd contamination of facility water reservoirs as the source of the high prevalence of this species. M. simiae (29)(30)(31). In Israel, M. simiae is the most common NTM isolated from clinical specimens; the species usually colonizes damaged lungs (30,31).…”

Section: Discussionmentioning

confidence: 99%

Multicenter Cross-Sectional Study of Nontuberculous Mycobacterial Infections among Cystic Fibrosis Patients, Israel

Levy

Grisaru‐Soen

Lerner‐Geva

et al. 2008

Emerg. Infect. Dis.

180

179

View full text Add to dashboard Cite

This 2-year cross-sectional evaluation of nontuberculous mycobacterial (NTM) infections involved all Israeli medical centers that treat cystic fi brosis patients. The study comprised 186 patients whose sputum was analyzed for NTM. The prevalence of NTM isolates was 22.6%, and 6.5% and 10.8% of the patients fulfi lled the 1997 and 2007 American Thoracic Society criteria for NTM lung disease, respectively. Mycobacterium simiae (40.5%), M. abscessus (31.0%), and M. avium complex (14.3%) were the most prevalent. Presence of Aspergillus spp. in sputum and the number of sputum specimens processed for mycobacteria were the most signifi cant predictors for isolation of NTM (odds ratio [OR] = 5.14, 95% confi dence interval [CI] 1.87-14.11 and OR = 1.47, 95% CI 1.17-1.85, respectively). The incidence of NTM pulmonary infections is increasing among cystic fi brosis patients, refl ecting the increase in longevity of such patients as well as environmental exposure to various species of mycobacteria.

show abstract

Section: Discussionmentioning

confidence: 99%

Multicenter Cross-Sectional Study of Nontuberculous Mycobacterial Infections among Cystic Fibrosis Patients, Israel

Levy

Grisaru‐Soen

Lerner‐Geva

et al. 2008

Emerg. Infect. Dis.

180

179

View full text Add to dashboard Cite

show abstract

“…M. simiae was the third most common mycobacterium identified in one laboratory in Arizona in 1994-1995 and at a university hospital in San Antonio, Texas, in 1983-1993 [21,22]. It is unclear whether these situations represent a pseudo-outbreak situation, because no environmental source was identified or linked to the clinical isolates.…”

Section: Discussionmentioning

confidence: 99%

“…There are geographic variations in the frequency of isolation of M. simiae, with Cuba, the southwestern United States, Israel, and, recently, Guadeloupe reporting outbreaks and/or increased frequency of isolation of M. simiae [21][22][23][24][25]. Isolates recovered from humans are estimated to be clinically relevant in 9%-21% of specimens [21,22,26].…”

Section: Simiae Isolates Were First Recovered In 1965 Frommentioning

confidence: 99%

See 1 more Smart Citation

Mycobacterium simiaePseudo‐outbreak Resulting from a Contaminated Hospital Water Supply in Houston, Texas

et al. 2002

View full text Add to dashboard Cite

Various species of nontuberculous mycobacteria are known to cause nosocomial pseudo-outbreaks, but there have been no detailed reports of nosocomial Mycobacterium simiae pseudo-outbreaks. From April 1997 through February 2001, we recovered 65 M. simiae isolates from 62 patients at a community teaching hospital in Houston, Texas. The organism was grown in various water samples obtained in the hospital building and in professional building 1 but not in professional building 2, which has a separate water supply system. Thirtyone environmental and human outbreak-related M. simiae isolates had indistinguishable or closely related patterns on pulsed-field gel electrophoresis and were considered clonal. M. simiae can be a cause of nosocomial pseudo-outbreaks. The reservoir for this pseudo-outbreak was identified as a contaminated hospital water supply.Nontuberculous mycobacteria (NTM) were described in clinical specimens as early as 1885. However, their importance as pathogens in humans has been overshadowed by Mycobacterium tuberculosis. With the improvements in techniques for the isolation and identification of mycobacteria and the control of tuberculosis, the importance of NTM, especially in immunocompromised hosts, has become recognized. One of the more important biological traits of NTM is their capacity to survive and grow in water, despite being

show abstract

“…avium complex [17,18], M. kansasii [2], and Mycobactesimiae [5]. Its resistance among isolates of M. tuberculosis rium haemophilum [19].…”

Section: Aminoglycosides Have Been a Major Component Of Therapymentioning

confidence: 99%

A Single 16S Ribosomal RNA Substitution Is Responsible for Resistance to Amikacin and Other 2‐Deoxystreptamine Aminoglycosides inMycobacterium abscessusandMycobacterium chelonae

Prammananan¹,

Sander²,

Brown³

et al. 1998

J INFECT DIS

207

152

View full text Add to dashboard Cite

Twenty-six clinical isolates of Mycobacterium abscessus resistant to amikacin were identified. Most isolates were from patients with posttympanostomy tube placement otitis media or patients with cystic fibrosis who had received aminoglycoside therapy. Isolates were highly resistant (MICs ú1024 mg/mL) to amikacin, kanamycin, gentamicin, tobramycin, and neomycin (all 2-deoxystreptamine aminoglycosides) but not to streptomycin. Sequencing of their 16S ribosomal (r) RNA revealed that 16 (94%) of 17 had an AjG mutation at position 1408. In vitro -selected amikacinresistant mutants of M. abscessus and Mycobacterium chelonae had the same resistance phenotype, and 15 mutants all had the same AjG substitution at position 1408. Introducing an rRNA operon from Mycobacterium smegmatis with a mutated AjG at this position into a single functional allelic rRNA mutant of M. smegmatis produced the same aminoglycoside resistance phenotype. These studies demonstrate this 16S rRNA mutation is responsible for amikacin resistance in M. abscessus, which has only one copy of the rRNA operon. Aminoglycosides have been a major component of therapyKanamycin and the closely related amikacin are used for for mycobacterial diseases since the recognition of the remarktreatment of multidrug resistant tuberculosis [13]. [19]. The genetic basis of mycobacterial is complex, with high-level resistance associated with point resistance to amikacin, kanamycin, and tobramycin has, until mutations involving the ribosomal protein S12 (rpsL gene) and recently [20,21], been unknown. the 16S ribosomal RNA (rRNA) gene (rrs) [6 -11]. The 16S Phenotypic studies have shown that spontaneous mutants rRNA gene region that is mutated involves a pseudoknot strucselected in the laboratory for resistance to amikacin, kanamyture that is believed to be stabilized by the presence of the cin, and tobramycin (2-deoxystreptamine aminoglycosides) are S12 protein [9]. Low-level resistance to streptomycin in M.not cross-resistant to streptomycin for either M. tuberculosis tuberculosis is yet to be explained on the basis of genetic [22] or the rapidly growing mycobacteria [23]. In addition, alterations [12] but is believed to result from mutations involvrecent studies with Mycobacterium smegmatis have suggested ing cell wall transport [7].that the 16S rRNA position 1408 (Escherichia coli numbering system) may be important for resistance to amikacin, tobramycin, and gentamicin [20,21]. In the present study, we inves-

show abstract

Clinical isolates of Mycobacterium simiae in San Antonio, Texas. An 11-yr review.

Cited by 61 publications

References 0 publications

Multicenter Cross-Sectional Study of Nontuberculous Mycobacterial Infections among Cystic Fibrosis Patients, Israel

Multicenter Cross-Sectional Study of Nontuberculous Mycobacterial Infections among Cystic Fibrosis Patients, Israel

Mycobacterium simiaePseudo‐outbreak Resulting from a Contaminated Hospital Water Supply in Houston, Texas

A Single 16S Ribosomal RNA Substitution Is Responsible for Resistance to Amikacin and Other 2‐Deoxystreptamine Aminoglycosides inMycobacterium abscessusandMycobacterium chelonae

Contact Info

Product

Resources

About